Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of calycosin-7-glucoside in preparation of drugs for treating asthma

A technique of vervisoflavone glycosides and asthma, which is applied in the field of preparing medicines for treating allergic asthma, and can solve the problems of reducing the apoptosis rate of MCF-7 cells and the like

Inactive Publication Date: 2017-04-05
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have reported that low concentrations of calycosin (2, 4 and 8 μmol / L) promote the proliferation of MCF-7 cells, and high concentrations of calycosin (16 and 32 μmol / L) inhibit the proliferation of MCF-7 cells in a dose-dependent manner; at the same time, Low concentrations of calycosin can reduce the apoptosis rate of MCF-7 cells; other studies have shown that calycosin has a significant inhibitory effect on K562 cells. The industry believes that it can block the cell growth cycle in the G0 / G1 phase and reduce the intracellular Cyclin The level of D1 mRNA may be the main mechanism of its inhibition of K562 cell growth; another study showed that calycosin can inhibit the transformation of endothelial cells (ECV-304) into myofibroblasts induced by TGF-β1, and has the effect of protecting endothelial cells. However, so far, there have been no reports on the use of acteolin glycosides in the preparation of drugs for the treatment of allergic asthma, especially the regulation of acteolin glycosides on ovalbumin OVA-induced asthma models is rarely reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of calycosin-7-glucoside in preparation of drugs for treating asthma
  • Use of calycosin-7-glucoside in preparation of drugs for treating asthma
  • Use of calycosin-7-glucoside in preparation of drugs for treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Effect of actcocoside on AHR of airway hyperresponsiveness in mouse asthma model induced by ovalbumin

[0026] 60 female BALB / c mice aged 7 weeks in healthy and clean grade, with a body weight of 16-18 g (provided by Shanghai Xipuerbikai Experimental Animal Co., Ltd.), were randomly divided into 6 groups, 10 in each group, namely the normal control group ( NC), asthma model group (AS), dexamethasone intervention group (DEX), verbascoside low, medium and high dose intervention groups (CL, CM, CH); mice were given a one-time intraperitoneal injection of 20ug from the 0th day Oval protein and 2mg of aluminum hydroxide in physiological saline suspension 0.2ml, make mice in a sensitized state. The sensitization was repeated three times in the same way on the 7th, 14th, and 21st days respectively; from the 25th day, 3% ovalbumin was inhaled by ultrasonic atomization, each time for about 30 minutes to induce asthma; Cyanosis, nodding breathing, and unsteady standing...

Embodiment 2

[0027] Example 2 Effect of Actascoisoflavone on Airway Inflammation in Ovalbumin-Induced Mouse Asthma Model

[0028] The right lung tissue was taken, rinsed with normal saline, soaked and fixed in 4% neutral formaldehyde, embedded in paraffin, stained with HE, and observed for inflammatory changes under a light microscope. Inflammatory cell infiltration such as cells, lymphocytes, macrophages and eosinophils, and the intervention of acteocoside can significantly reduce the inflammatory changes such as inflammatory cell infiltration and alveolar congestion in the airway wall of mice.

Embodiment 3

[0029] Example 3 Effect of Actascoisoflavone Glycoside on Inflammatory Cells in Ovalbumin-Induced Mouse Asthma Model BALF

[0030]After the mouse completed the pulmonary function test, a tracheal lavage needle was inserted into the left bronchus, the right main bronchus and right lung were ligated by thoracotomy, and the left lung was lavaged with 0.3ml PBS, repeated twice. After the recovered BALF was centrifuged at 800g×10min at 4°C, the cell pellet was resuspended with 100ul PBS solution, and the white blood cell differential count was performed. Compared with the normal group, the total white blood cell count (WBC), neutrophil (NEU ), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS) were significantly increased. Verbacosin can significantly reduce WBC, NEU, MON, and EOS in BALF. and the number of BAS cells (p<0.05).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the pharmaceutical field, relates to a novel medicinal use of calycosin-7-glucoside and especially relates to a use of calycosin-7-glucoside in preparation of drugs for treating asthma and especially for treating allergic asthma. The results of an in-vivo animal experiment and an in-vitro CD4+T cell culture experiment show that calycosin-7-glucoside has effects on an ovalbumin-induced mouse asthma model and CD4+T cells isolated from spleen, and can significantly reduce airway hyperresponsiveness of asthmatic mice, inhibit airway inflammation, reduce the number of inflammatory cells in an alveolar lavage fluid, inhibit chemokine secretion, promote Th1 cell differentiation, inhibit IL-17A, promote IFN-gamma and IL-10 secretion and inhibit NF-kappa B activation. The calycosin-7-glucoside can be used as a single ingredient for preparation of drugs for treating asthma or allergic asthma.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the new medicinal use of acteocoside, in particular to the use of actcoisoflavone in medicines for treating asthma, especially the use in preparing medicines for treating allergic asthma. Background technique [0002] Studies have shown that asthma is a chronic airway inflammatory disease involving a variety of cells and cellular components. This chronic inflammation leads to increased airway responsiveness to a variety of stimuli, reversible airflow limitation, and recurrent episodes of asthma. Wheezing, shortness of breath, chest tightness, coughing and other symptoms. Studies have reported that asthmatic inflammation is mainly characterized by the infiltration and accumulation of various inflammatory cells in the airway, mainly T lymphocytes, mast cells, eosinophils and neutrophils. These inflammatory cells interact and secrete multiple These inflammatory mediators and cytokines interac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P11/06A61P29/00
Inventor 董竞成魏颖张红英杜鑫罗清莉吕玉宝
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com